Sarepta Therapeutics (NASDAQ: SRPT) hit by FDA boxed warning as ELEVIDYS loses non‑ambulatory DMD indication

Sarepta Therapeutics (NASDAQ: SRPT) has been dealt a regulatory setback following a United States Food and Drug Administration decision to revise the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy. The updated label adds a boxed warning for acute serious liver injury and acute liver failure, and removes the indication for non-ambulatory patients after post-marketing reports of fatal liver complications.

The label revision narrows ELEVIDYS’ approved use to ambulatory DMD patients aged four years and older with confirmed DMD gene mutations. Sarepta Therapeutics said it will soon initiate a new clinical study to evaluate a sirolimus-based immunosuppressive regimen aimed at restoring treatment access for the excluded patient group. The revised safety profile reflects real-world experience from more than 1,100 patients treated globally and marks a more cautious regulatory stance toward high-risk populations in gene therapy.

Why has the non-ambulatory DMD indication been removed and what is Sarepta’s path forward?

The decision to remove the non-ambulatory indication from the ELEVIDYS label stems from serious safety signals that emerged post-approval. Sarepta Therapeutics cited the occurrence of fatal liver injury events, especially in non-ambulatory patients, as a key factor behind the change. According to the revised prescribing information, the risk of acute liver failure in this population prompted the regulator to restrict the approved use to ambulatory patients aged four years and older with a confirmed mutation in the DMD gene.

Sarepta Therapeutics has responded by proposing a revised trial using an augmented sirolimus immunosuppressive regimen, designed to mitigate the liver-related toxicity. This clinical effort is aimed at demonstrating that, with the right pre-infusion immune suppression, the therapy can be made safer for non-ambulatory patients. The company intends to initiate the study promptly and will seek the agency’s concurrence to restore treatment access for this critical patient group.

Analysts following Sarepta Therapeutics believe that although this is a regulatory setback in the near term, the proactive pivot to new safety protocols may help the American biotech firm regain lost ground if future data proves favorable. The strategy also reinforces the company’s emphasis on regulatory collaboration and safety-first patient access.

What changes were made to immunosuppression protocols and infection monitoring guidance?

The updated label includes detailed instructions for managing immunosuppression to minimize the risk of infection and inflammatory complications following ELEVIDYS infusion. A modified corticosteroid regimen is now included as part of the prescribing information, which must be administered both before and after the gene therapy dose. Sarepta Therapeutics has emphasized that this protocol is not optional but a critical part of risk mitigation.

Additionally, the updated label recommends weekly liver function testing for a minimum of three months post-infusion. Monitoring must continue beyond that window if any abnormalities persist. Patients are advised to stay close to a healthcare facility capable of responding to serious liver events for at least two months after the infusion. Physicians are also instructed to seek prompt consultation with a liver specialist at the first signs of acute liver dysfunction.

The revised warnings also include a new precaution on serious infections. The immunosuppressive protocols required for ELEVIDYS administration, including systemic corticosteroids and any additional agents, may render patients more vulnerable to life-threatening respiratory infections. Sarepta Therapeutics referenced post-marketing cases of fatal infections in patients receiving ELEVIDYS alongside these immune-modulating drugs.

In light of this, the label now advises healthcare professionals to ensure that patients receive all age-appropriate vaccinations before beginning corticosteroid treatment. Patients with active infections or those who have been vaccinated within the previous four weeks are not recommended for immediate treatment due to heightened safety concerns.

What risks have been prioritized in the new safety profile and how are prescribers expected to manage them?

The revised ELEVIDYS label outlines a range of severe and life-threatening risks that require rigorous clinical oversight. The most prominently emphasized risks include acute liver injury, liver failure, myocarditis, serious infections, immune-mediated myositis, and infusion-related reactions.

In terms of liver toxicity, onset of liver damage typically begins within eight weeks post-infusion. Fatal liver failure has occurred particularly in non-ambulatory patients, and in some instances, complications such as mesenteric vein thrombosis and bowel necrosis were also reported. Sarepta Therapeutics now advises against dosing patients with any form of preexisting liver impairment, including elevated gamma-glutamyl transferase or total bilirubin levels, or active liver infections.

For myocarditis, the updated guidance notes that cases have been reported as early as 24 hours and as late as more than one year following infusion. Physicians are instructed to measure troponin-I levels prior to treatment and weekly for at least a month afterward, with continued monitoring as clinically indicated. Patients with preexisting cardiac dysfunction, especially those with impaired left ventricular ejection fraction, may face higher risks of poor outcomes if myocarditis develops.

Immune-mediated myositis has also been flagged in the updated information. These events, which have included life-threatening muscle weakness, have occurred approximately one month post-treatment. Sarepta Therapeutics reports that patients with deletions involving exons 1 through 17 and/or exons 59 through 71 in the DMD gene may be more susceptible, but all patients should be advised to report new or unexplained muscle symptoms immediately.

Infusion-related reactions, including hypersensitivity and anaphylaxis, have occurred in both clinical and post-approval settings. Sarepta Therapeutics recommends that ELEVIDYS be administered in a clinical environment equipped to manage acute infusion reactions and anaphylaxis. Observation should continue for at least three hours post-infusion, and in cases of severe reaction, infusion should be stopped and appropriate care administered.

How do preexisting anti-AAVrh74 antibodies affect patient eligibility and treatment outcomes?

Like many adeno-associated virus (AAV)-based gene therapies, ELEVIDYS faces limitations related to preexisting immunity against the vector. Sarepta Therapeutics has stated that patients with elevated anti-AAVrh74 binding antibodies, defined as a titer greater than or equal to 1:400, may experience reduced efficacy due to impaired transgene expression.

As a result, the updated prescribing information recommends that all patients undergo antibody screening before being considered eligible for treatment. Following administration, all treated patients are expected to develop anti-AAVrh74 antibodies, further limiting the potential for redosing or crossover to future AAV-based therapies.

This aspect of patient selection underscores a broader challenge for the gene therapy field: how to ensure that eligible candidates are identified early, before natural immunity or viral exposure renders them less responsive to single-dose therapies. Analysts believe this will be a major consideration in future trial designs and commercialization strategies not only for Sarepta Therapeutics but for other players in the genetic medicine landscape.

What is the investor sentiment following this label change and how might it shape Sarepta’s commercial trajectory?

Shares of Sarepta Therapeutics have come under scrutiny following the label revision. While full post-announcement market data is still unfolding, the overall sentiment among institutional investors appears to be cautious but not universally negative. The narrowed label restricts Sarepta’s commercial scope in the short term, but the company’s rapid move to pursue a targeted trial with an updated immunosuppression strategy has been viewed as a signal of strong regulatory engagement and clinical agility.

Industry analysts acknowledge that losing access to the non-ambulatory segment reduces the near-term revenue potential of ELEVIDYS. However, given the rarity and urgency of Duchenne muscular dystrophy, especially in pediatric populations, the market opportunity remains significant even with the restricted indication. The firm’s continued leadership in DMD and its broader pipeline in neuromuscular and cardiac indications help cushion the impact of this particular development.

Looking forward, investor focus will be closely trained on Sarepta Therapeutics’ timeline for launching the sirolimus-based trial, any interim safety readouts, and the company’s ability to secure an eventual label expansion. The durability of ELEVIDYS outcomes in ambulatory patients, as well as any evolving safety data, will also play a central role in determining long-term value.

What are the key takeaways from the updated ELEVIDYS gene therapy label?

• The United States Food and Drug Administration has approved a revised label for ELEVIDYS (delandistrogene moxeparvovec-rokl), adding a boxed warning for acute serious liver injury and acute liver failure.

• Sarepta Therapeutics has removed the non-ambulatory indication for Duchenne muscular dystrophy from the approved use, narrowing the therapy’s scope to ambulatory patients aged four years and older with confirmed DMD gene mutations.

• The company plans to begin a clinical study using an enhanced sirolimus-based immunosuppression regimen to potentially reintroduce the non-ambulatory population into the treatment pathway.

• Revised guidance includes a stricter corticosteroid regimen, mandatory weekly liver function monitoring for three months, and a two-month proximity requirement to a medical facility post-infusion.

• New warnings highlight increased susceptibility to serious infections, myocarditis, immune-mediated myositis, and infusion-related hypersensitivity reactions.

• ELEVIDYS is now contraindicated in patients with deletions in exon 8 and/or exon 9 of the DMD gene, as well as those with liver impairment or recent infection history.

• Sarepta Therapeutics also warns against administering ELEVIDYS in patients with elevated anti-AAVrh74 antibody titers, due to reduced therapeutic efficacy.

• The most common adverse events observed include vomiting, nausea, liver injury, fever, thrombocytopenia, and elevated troponin-I levels.

• Investor sentiment remains cautious as the commercial reach of ELEVIDYS is reduced in the short term, though analysts are watching closely for the timeline and data from the upcoming sirolimus study.

• The updated label underscores the rising importance of real-world safety surveillance in gene therapy and signals a more conservative regulatory posture toward high-risk populations.